Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS
Wilson Therapeutics AB (publ), announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for WTX101 for the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). WTX101 (bis-choline tetrathiomolybdate) is an investigational first-in-class copper-protein binding agent with a unique mechanism of action. ALS is a neurodegenerative disease, in which the nerve cells controlling the body’s muscles gradually degenerate, leading to general paralysis and respiratory failure. Median survival for an ALS patient is three to